8,738 XNAS Volume
XNAS 04 Apr, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Praveen Tyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Lisa Walters Hoffert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| David A. Hollander | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Aron Shapiro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Brian M. Strem | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 31,883 | 31,883 | - | - | Stock Option (right to buy) | |
| Brian M. Strem | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 15,941 | 46,103 (0%) | 0% | 0 | Common Stock | |
| Eric J. Daniels | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 7,772 | 26,375 (0%) | 0% | 0 | Common Stock | |
| Eric J. Daniels | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 15,543 | 15,543 | - | - | Stock Option (right to buy) | |
| Erin Parsons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Melissa Tosca | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 7,772 | 21,371 (0%) | 0% | 0 | Common Stock | |
| Melissa Tosca | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 15,543 | 15,543 | - | - | Stock Option (right to buy) | |
| Carmine Stengone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Carmine Stengone | Director | Purchase of securities on an exchange or from another person at price $ 3.68 per share. | 11 Sep 2024 | 1,250 | 1,250 (0%) | 0% | 3.7 | 4,600 | Common Stock |
| Aron Shapiro | Director | Purchase of securities on an exchange or from another person at price $ 3.60 per share. | 10 Sep 2024 | 3,000 | 3,000 (0%) | 0% | 3.6 | 10,800 | Common Stock |
| Praveen Tyle | Director | Purchase of securities on an exchange or from another person at price $ 3.96 per share. | 19 Aug 2024 | 5,000 | 5,014 (0%) | 0% | 4.0 | 19,800 | Common Stock |
| Lisa Walters Hoffert | Director | Purchase of securities on an exchange or from another person at price $ 3.86 per share. | 19 Aug 2024 | 1,250 | 1,250 (0%) | 0% | 3.9 | 4,825 | Common Stock |
| Melissa Tosca | CFO | Purchase of securities on an exchange or from another person at price $ 3.21 per share. | 14 Aug 2024 | 2,000 | 13,599 (0%) | 0% | 3.2 | 6,420 | Common Stock |
| Praveen Tyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 1,778 | 1,778 | - | - | Stock Option (right to buy) | |
| Lisa Walters Hoffert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 1,778 | 1,778 | - | - | Stock Option (right to buy) | |
| David A. Hollander | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 1,778 | 1,778 | - | - | Stock Option (right to buy) | |
| Aron Shapiro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 1,778 | 1,778 | - | - | Stock Option (right to buy) | |
| Brian M. Strem | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 15,629 | 30,160 (0%) | 0% | 0 | Common Stock | |
| Brian M. Strem | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 31,259 | 31,259 | - | - | Stock Option (right to buy) | |
| Eric J. Daniels | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 14,710 | 14,710 | - | - | Stock Option (right to buy) | |
| Eric J. Daniels | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 7,355 | 18,577 (0%) | 0% | 0 | Common Stock | |
| Erin Parsons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 1,778 | 1,778 | - | - | Stock Option (right to buy) | |
| Melissa Tosca | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 15,239 | 15,239 | - | - | Stock Option (right to buy) | |
| Melissa Tosca | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 7,620 | 11,599 (0%) | 0% | 0 | Common Stock | |
| Carmine Stengone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 1,778 | 1,778 | - | - | Stock Option (right to buy) | |
| Eric J. Daniels | Chief Development Officer | Purchase of securities on an exchange or from another person at price $ 5.29 per share. | 14 Jun 2024 | 1,431 | 11,222 (0%) | 0% | 5.3 | 7,570 | Common Stock |
| Melissa Tosca | EVP Finance | Purchase of securities on an exchange or from another person at price $ 5.25 per share. | 14 Jun 2024 | 100 | 3,979 (0%) | 0% | 5.3 | 525 | Common Stock |
| Brian M. Strem | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 5.00 per share. | 13 Jun 2024 | 3,000 | 14,531 (0%) | 0% | 5.0 | 14,997 | Common Stock |
| Erin Parsons | Director | Purchase of securities on an exchange or from another person at price $ 4.88 per share. | 13 Jun 2024 | 5,260 | 5,260 (0%) | 0% | 4.9 | 25,669 | Common Stock |
| Paul G. Chaney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Praveen Tyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Kenneth L Gayron | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| David Hollander | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Aron Shapiro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Brian M. Strem | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 3.83 per share. | 03 Mar 2023 | 15,600 | 28,783 (0%) | 0% | 3.8 | 59,748 | Common Stock |
| Brian M. Strem | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 10,400 | 10,400 | - | - | Stock Option (right to buy) | |
| Eric J. Daniels | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 15,600 | 25,838 (0%) | 0% | 0 | Common Stock | |
| Eric J. Daniels | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 10,400 | 10,400 | - | - | Stock Option (right to buy) | |
| Erin Parsons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Melissa Tosca | EVP Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 2,400 | 7,400 (0%) | 0% | 0 | Common Stock | |
| Melissa Tosca | EVP Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 1,600 | 1,600 | - | - | Stock Option (right to buy) | |
| Brian M. Strem | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2022 | 18,750 | 18,750 | - | - | Stock Option (right to buy) | |
| Brian M. Strem | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2022 | 12,500 | 13,183 (0%) | 0% | 0 | Common Stock | |
| Eric J. Daniels | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2022 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Eric J. Daniels | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2022 | 10,000 | 10,238 (0%) | 0% | 0 | Common Stock | |
| Melissa Tosca | EVP of Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2022 | 2,500 | 2,500 (0%) | 0% | 0 | Common Stock | |
| Melissa Tosca | EVP of Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2022 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Paul G. Chaney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Praveen Tyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Kenneth L Gayron | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Sarah M. Romano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| David Hollander | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| David Hollander | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 4,000 | 4,000 | - | - | Stock Option (right to buy) | |
| Aron Shapiro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Brian M. Strem | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Eric J. Daniels | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Erin Parsons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 4,000 | 4,000 | - | - | Stock Option (right to buy) | |
| Erin Parsons | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Stephen From | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.08 per share. | 05 Jan 2022 | 326 | 67,693 (1%) | 0% | 1.1 | 352 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.08 per share. | 05 Jan 2022 | 114 | 22,854 (0%) | 0% | 1.1 | 123 | Common Stock |
| Stephen From | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.30 per share. | 07 Dec 2021 | 273 | 68,019 (1%) | 0% | 1.3 | 355 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.30 per share. | 07 Dec 2021 | 91 | 22,968 (0%) | 0% | 1.3 | 118 | Common Stock |
| Stephen From | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.98 per share. | 02 Nov 2021 | 250 | 68,292 (1%) | 0% | 2.0 | 495 | Common Stock |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.98 per share. | 02 Nov 2021 | 62 | 15,136 (0%) | 0% | 2.0 | 123 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.98 per share. | 02 Nov 2021 | 83 | 23,059 (0%) | 0% | 2.0 | 164 | Common Stock |
| Brian M. Strem | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2021 | 9,517 | 9,517 (0%) | 0% | - | Common Stock | |
| Brian M. Strem | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 1.41 per share. | 21 Oct 2021 | 17,853 | 27,370 (0%) | 0% | 1.4 | 25,173 | Common Stock |
| Eric J. Daniels | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Oct 2021 | 9,520 | 9,520 (0%) | 0% | - | Common Stock | |
| Stephen From | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.01 per share. | 04 Oct 2021 | 249 | 68,542 (1%) | 0% | 2.0 | 500 | Common Stock |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.02 per share. | 04 Oct 2021 | 62 | 15,198 (0%) | 0% | 2.0 | 125 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.01 per share. | 04 Oct 2021 | 83 | 23,142 (0%) | 0% | 2.0 | 167 | Common Stock |
| Stephen From | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.81 per share. | 02 Sep 2021 | 253 | 68,791 (1%) | 0% | 1.8 | 458 | Common Stock |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.80 per share. | 02 Sep 2021 | 61 | 15,260 (0%) | 0% | 1.8 | 110 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.81 per share. | 02 Sep 2021 | 84 | 23,225 (0%) | 0% | 1.8 | 152 | Common Stock |
| Stephen From | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.40 per share. | 03 Aug 2021 | 261 | 69,044 (1%) | 0% | 2.4 | 626 | Common Stock |
| Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.40 per share. | 03 Aug 2021 | 65 | 15,378 (0%) | 0% | 2.4 | 156 | Common Stock |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.40 per share. | 03 Aug 2021 | 63 | 15,321 (0%) | 0% | 2.4 | 151 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.40 per share. | 03 Aug 2021 | 87 | 23,309 (0%) | 0% | 2.4 | 209 | Common Stock |
| Brian M. Strem | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2021 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Stephen From | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 02 Jul 2021 | 877 | 69,305 (1%) | 0% | 3.7 | 3,245 | Common Stock |
| Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 02 Jul 2021 | 160 | 15,443 (0%) | 0% | 3.7 | 592 | Common Stock |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 02 Jul 2021 | 154 | 15,384 (0%) | 0% | 3.7 | 570 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.70 per share. | 02 Jul 2021 | 180 | 23,396 (0%) | 0% | 3.7 | 666 | Common Stock |
| Stephen From | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.19 per share. | 04 Jun 2021 | 878 | 70,182 (1%) | 0% | 4.2 | 3,679 | Common Stock |
| Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.19 per share. | 04 Jun 2021 | 155 | 15,603 (0%) | 0% | 4.2 | 649 | Common Stock |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.19 per share. | 04 Jun 2021 | 155 | 15,538 (0%) | 0% | 4.2 | 649 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.19 per share. | 04 Jun 2021 | 180 | 23,576 (0%) | 0% | 4.2 | 754 | Common Stock |
| Stephen From | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.13 per share. | 04 May 2021 | 889 | 71,060 (1%) | 0% | 4.1 | 3,672 | Common Stock |
| Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.13 per share. | 04 May 2021 | 158 | 15,758 (0%) | 0% | 4.1 | 653 | Common Stock |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.13 per share. | 04 May 2021 | 191 | 15,693 (0%) | 0% | 4.1 | 789 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.13 per share. | 04 May 2021 | 177 | 23,756 (0%) | 0% | 4.1 | 731 | Common Stock |
| Kenneth L Gayron | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2021 | 4,000 | 4,000 | - | - | Stock Option (right to buy) | |
| Aron Shapiro | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Apr 2021 | 4,000 | 4,000 | - | - | Stock Option (right to buy) | |
| Stephen From | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.94 per share. | 08 Apr 2021 | 899 | 71,949 (1%) | 0% | 4.9 | 4,441 | Common Stock |
| Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.94 per share. | 08 Apr 2021 | 194 | 15,916 (0%) | 0% | 4.9 | 958 | Common Stock |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.94 per share. | 08 Apr 2021 | 192 | 15,884 (0%) | 0% | 4.9 | 948 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.94 per share. | 08 Apr 2021 | 180 | 23,933 (0%) | 0% | 4.9 | 889 | Common Stock |
| Stephen From | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.46 per share. | 03 Mar 2021 | 898 | 72,848 (1%) | 0% | 5.5 | 4,903 | Common Stock |
| Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.46 per share. | 03 Mar 2021 | 192 | 16,110 (0%) | 0% | 5.5 | 1,048 | Common Stock |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.46 per share. | 03 Mar 2021 | 192 | 16,076 (0%) | 0% | 5.5 | 1,048 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.46 per share. | 03 Mar 2021 | 218 | 24,113 (0%) | 0% | 5.5 | 1,190 | Common Stock |
| Paul G. Chaney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 3,333 | 3,333 | - | - | Stock Option (right to buy) | |
| Thomas E. Hancock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 3,333 | 3,333 | - | - | Stock Option (right to buy) | |
| Praveen Tyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 3,333 | 3,333 | - | - | Stock Option (right to buy) | |
| Stephen From | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Stephen From | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.34 per share. | 01 Feb 2021 | 3,542 | 73,746 (1%) | 0% | 6.3 | 22,456 | Common Stock |
| Michael Manzo | VP of Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.34 per share. | 01 Feb 2021 | 990 | 16,302 (0%) | 0% | 6.3 | 6,277 | Common Stock |
| Morton F. Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 3,333 | 3,333 | - | - | Stock Option (right to buy) | |
| Bernard Malfroy-Camine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 3,333 | 3,333 | - | - | Stock Option (right to buy) | |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.34 per share. | 01 Feb 2021 | 988 | 16,268 (0%) | 0% | 6.3 | 6,264 | Common Stock |
| Brenda Mann | VP of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Sarah M. Romano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.34 per share. | 01 Feb 2021 | 1,282 | 24,331 (0%) | 0% | 6.3 | 8,128 | Common Stock |
| Franz Obermayr | Acting CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Stephen From | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.85 per share. | 04 Jan 2021 | 705 | 77,288 (1%) | 0% | 4.8 | 3,419 | Common Stock |
| Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.85 per share. | 04 Jan 2021 | 115 | 17,292 (0%) | 0% | 4.9 | 558 | Common Stock |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.85 per share. | 04 Jan 2021 | 115 | 17,256 (0%) | 0% | 4.9 | 558 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.85 per share. | 04 Jan 2021 | 115 | 25,613 (0%) | 0% | 4.9 | 558 | Common Stock |
| Stephen From | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.51 per share. | 02 Nov 2020 | 623 | 78,581 (1%) | 0% | 3.5 | 2,187 | Common Stock |
| Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.51 per share. | 02 Nov 2020 | 97 | 17,498 (0%) | 0% | 3.5 | 340 | Common Stock |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.51 per share. | 02 Nov 2020 | 96 | 17,462 (0%) | 0% | 3.5 | 337 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.51 per share. | 02 Nov 2020 | 97 | 25,819 (0%) | 0% | 3.5 | 340 | Common Stock |
| Stephen From | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.88 per share. | 02 Oct 2020 | 631 | 79,204 (1%) | 0% | 3.9 | 2,448 | Common Stock |
| Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.88 per share. | 02 Oct 2020 | 98 | 17,595 (0%) | 0% | 3.9 | 380 | Common Stock |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.88 per share. | 02 Oct 2020 | 98 | 17,558 (0%) | 0% | 3.9 | 380 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.88 per share. | 02 Oct 2020 | 98 | 25,916 (0%) | 0% | 3.9 | 380 | Common Stock |
| Stephen From | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.94 per share. | 02 Sep 2020 | 628 | 79,835 (1%) | 0% | 3.9 | 2,474 | Common Stock |
| Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.94 per share. | 02 Sep 2020 | 97 | 17,693 (0%) | 0% | 3.9 | 382 | Common Stock |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.94 per share. | 02 Sep 2020 | 97 | 17,656 (0%) | 0% | 3.9 | 382 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.94 per share. | 02 Sep 2020 | 97 | 26,014 (0%) | 0% | 3.9 | 382 | Common Stock |
| Stephen From | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.11 per share. | 04 Aug 2020 | 615 | 80,463 (1%) | 0% | 4.1 | 2,528 | Common Stock |
| Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.11 per share. | 04 Aug 2020 | 95 | 17,790 (0%) | 0% | 4.1 | 390 | Common Stock |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.11 per share. | 04 Aug 2020 | 92 | 17,753 (0%) | 0% | 4.1 | 378 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.11 per share. | 04 Aug 2020 | 95 | 26,111 (0%) | 0% | 4.1 | 390 | Common Stock |
| Stephen From | Director, President and CEO, Ten Percent Owner | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.82 per share. | 02 Jul 2020 | 625 | 81,078 (1%) | 0% | 4.8 | 3,013 | Common Stock |
| Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.82 per share. | 02 Jul 2020 | 97 | 17,885 (0%) | 0% | 4.8 | 468 | Common Stock |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.82 per share. | 02 Jul 2020 | 94 | 17,845 (0%) | 0% | 4.8 | 453 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.82 per share. | 02 Jul 2020 | 97 | 26,206 (0%) | 0% | 4.8 | 468 | Common Stock |
| Stephen From | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.11 per share. | 03 Jun 2020 | 627 | 81,703 (1%) | 0% | 5.1 | 3,204 | Common Stock |
| Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.11 per share. | 03 Jun 2020 | 94 | 17,982 (0%) | 0% | 5.1 | 480 | Common Stock |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.11 per share. | 03 Jun 2020 | 94 | 17,939 (0%) | 0% | 5.1 | 480 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.11 per share. | 03 Jun 2020 | 94 | 26,303 (0%) | 0% | 5.1 | 480 | Common Stock |
| Stephen From | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.10 per share. | 05 May 2020 | 617 | 82,330 (1%) | 0% | 5.1 | 3,147 | Common Stock |
| Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.10 per share. | 05 May 2020 | 93 | 18,076 (0%) | 0% | 5.1 | 474 | Common Stock |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.10 per share. | 05 May 2020 | 113 | 18,033 (0%) | 0% | 5.1 | 576 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.10 per share. | 05 May 2020 | 93 | 26,397 (0%) | 0% | 5.1 | 474 | Common Stock |
| Stephen From | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.97 per share. | 02 Apr 2020 | 670 | 82,947 (1%) | 0% | 5.0 | 3,330 | Common Stock |
| Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.97 per share. | 02 Apr 2020 | 122 | 18,169 (0%) | 0% | 5.0 | 606 | Common Stock |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.97 per share. | 02 Apr 2020 | 122 | 18,146 (0%) | 0% | 5.0 | 606 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.97 per share. | 02 Apr 2020 | 122 | 26,490 (0%) | 0% | 5.0 | 606 | Common Stock |
| Stephen From | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.00 per share. | 09 Mar 2020 | 712 | 83,617 (1%) | 0% | 5 | 3,560 | Common Stock |
| Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.01 per share. | 09 Mar 2020 | 130 | 18,291 (0%) | 0% | 5.0 | 651 | Common Stock |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.00 per share. | 09 Mar 2020 | 130 | 18,268 (0%) | 0% | 5 | 650 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.01 per share. | 09 Mar 2020 | 130 | 26,612 (0%) | 0% | 5.0 | 651 | Common Stock |
| Paul G. Chaney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2020 | 3,333 | 3,333 | - | - | Stock Option (right to buy) | |
| Thomas E. Hancock | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2020 | 3,333 | 3,333 | - | - | Stock Option (right to buy) | |
| Praveen Tyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2020 | 3,333 | 3,333 | - | - | Stock Option (right to buy) | |
| Stephen From | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2020 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Stephen From | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2020 | 20,000 | 84,329 (1%) | 0% | 0 | Common Stock | |
| Michael Manzo | VP of Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2020 | 7,500 | 18,421 (0%) | 0% | 0 | Common Stock | |
| Michael Manzo | VP of Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2020 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Morton F. Goldberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2020 | 3,333 | 3,333 | - | - | Stock Option (right to buy) | |
| Bernard Malfroy-Camine | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2020 | 3,333 | 3,333 | - | - | Stock Option (right to buy) | |
| Brenda Mann | VP of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2020 | 7,500 | 7,500 | - | - | Stock Option (right to buy) | |
| Brenda Mann | VP of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2020 | 7,500 | 18,398 (0%) | 0% | 0 | Common Stock | |
| Sarah M. Romano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2020 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Sarah M. Romano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2020 | 10,000 | 26,742 (0%) | 0% | 0 | Common Stock | |
| Stephen From | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.52 per share. | 03 Jan 2020 | 730 | 64,913 (1%) | 0% | 9.5 | 6,950 | Common Stock |
| Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.52 per share. | 03 Jan 2020 | 119 | 11,030 (0%) | 0% | 9.5 | 1,133 | Common Stock |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.52 per share. | 03 Jan 2020 | 119 | 11,007 (0%) | 0% | 9.5 | 1,133 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.52 per share. | 03 Jan 2020 | 119 | 16,851 (0%) | 0% | 9.5 | 1,133 | Common Stock |
| Stephen From | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.46 per share. | 18 Dec 2019 | 653 | 65,643 (1%) | 0% | 7.5 | 4,871 | Common Stock |
| Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.46 per share. | 18 Dec 2019 | 101 | 11,149 (0%) | 0% | 7.5 | 753 | Common Stock |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.46 per share. | 18 Dec 2019 | 101 | 11,126 (0%) | 0% | 7.5 | 753 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.46 per share. | 18 Dec 2019 | 101 | 16,970 (0%) | 0% | 7.5 | 753 | Common Stock |
| Morton F. Goldberg | None | Sale of securities on an exchange or to another person at price $ 6.93 per share. | 06 Dec 2019 | 1,961 | 0 (0%) | 0% | 6.9 | 13,590 | Common Stock |
| Morton F. Goldberg | None | Sale of securities on an exchange or to another person at price $ 4.29 per share. | 12 Nov 2019 | 2,001 | 1,961 (0%) | 0% | 4.3 | 8,584 | Common Stock |
| Stephen From | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.85 per share. | 05 Nov 2019 | 670 | 66,296 (1%) | 0% | 3.9 | 2,580 | Common Stock |
| Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.86 per share. | 05 Nov 2019 | 108 | 11,250 (0%) | 0% | 3.9 | 417 | Common Stock |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.85 per share. | 05 Nov 2019 | 107 | 11,227 (0%) | 0% | 3.9 | 412 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.85 per share. | 05 Nov 2019 | 108 | 17,071 (0%) | 0% | 3.9 | 416 | Common Stock |
| Stephen From | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.95 per share. | 09 Oct 2019 | 1,184 | 66,966 (1%) | 0% | 3.0 | 3,493 | Common Stock |
| Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.13 per share. | 09 Oct 2019 | 185 | 11,358 (0%) | 0% | 3.1 | 579 | Common Stock |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.12 per share. | 09 Oct 2019 | 184 | 11,334 (0%) | 0% | 3.1 | 574 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.10 per share. | 09 Oct 2019 | 185 | 17,179 (0%) | 0% | 3.1 | 574 | Common Stock |
| Stephen From | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.21 per share. | 06 Aug 2019 | 10,206 | 1,022,259 (22%) | 0% | 0.2 | 2,143 | Common Stock |
| Michael Manzo | VP of Engineering | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.21 per share. | 06 Aug 2019 | 1,649 | 173,147 (3%) | 0% | 0.2 | 346 | Common Stock |
| Brenda Mann | VP of Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.21 per share. | 06 Aug 2019 | 1,641 | 172,783 (3%) | 0% | 0.2 | 345 | Common Stock |
| Barbara Wirostko | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.21 per share. | 06 Aug 2019 | 1,641 | 403,893 (8%) | 0% | 0.2 | 345 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.21 per share. | 06 Aug 2019 | 1,649 | 260,464 (5%) | 0% | 0.2 | 346 | Common Stock |
| Stephen From | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.24 per share. | 11 Jul 2019 | 42,451 | 1,117,369 (24%) | 0% | 0.2 | 10,214 | Common Stock |
| Stephen From | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.24 per share. | 11 Jul 2019 | 42,452 | 1,074,917 (23%) | 0% | 0.2 | 10,002 | Common Stock |
| Stephen From | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.23 per share. | 11 Jul 2019 | 42,452 | 1,032,465 (22%) | 0% | 0.2 | 9,891 | Common Stock |
| Michael Manzo | VP of Engineering | Sale of securities on an exchange or to another person at price $ 0.24 per share. | 11 Jul 2019 | 6,583 | 187,963 (4%) | 0% | 0.2 | 1,584 | Common Stock |
| Michael Manzo | VP of Engineering | Sale of securities on an exchange or to another person at price $ 0.23 per share. | 11 Jul 2019 | 6,584 | 174,796 (3%) | 0% | 0.2 | 1,534 | Common Stock |
| Michael Manzo | VP of Engineering | Sale of securities on an exchange or to another person at price $ 0.24 per share. | 11 Jul 2019 | 6,583 | 181,380 (3%) | 0% | 0.2 | 1,551 | Common Stock |
| Brenda Mann | VP of Research & Development | Sale of securities on an exchange or to another person at price $ 0.24 per share. | 11 Jul 2019 | 6,349 | 187,124 (4%) | 0% | 0.2 | 1,528 | Common Stock |
| Brenda Mann | VP of Research & Development | Sale of securities on an exchange or to another person at price $ 0.23 per share. | 11 Jul 2019 | 6,350 | 174,424 (3%) | 0% | 0.2 | 1,480 | Common Stock |
| Brenda Mann | VP of Research & Development | Sale of securities on an exchange or to another person at price $ 0.24 per share. | 11 Jul 2019 | 6,350 | 180,774 (3%) | 0% | 0.2 | 1,496 | Common Stock |
| Barbara Wirostko | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 0.24 per share. | 11 Jul 2019 | 6,487 | 418,510 (9%) | 0% | 0.2 | 1,561 | Common Stock |
| Barbara Wirostko | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 0.24 per share. | 11 Jul 2019 | 6,488 | 412,022 (8%) | 0% | 0.2 | 1,529 | Common Stock |
| Barbara Wirostko | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 0.23 per share. | 11 Jul 2019 | 6,488 | 405,534 (8%) | 0% | 0.2 | 1,512 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.23 per share. | 11 Jul 2019 | 6,584 | 262,113 (5%) | 0% | 0.2 | 1,534 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.24 per share. | 11 Jul 2019 | 6,583 | 275,280 (5%) | 0% | 0.2 | 1,584 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.24 per share. | 11 Jul 2019 | 6,583 | 268,697 (5%) | 0% | 0.2 | 1,551 | Common Stock |
| Paul G. Chaney | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2019 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Thomas E. Hancock | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2019 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Praveen Tyle | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2019 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Stephen From | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2019 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Michael Manzo | Vice President of Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2019 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Morton F. Goldberg | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2019 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Bernard Malfroy-Camine | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2019 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Barbara Wirostko | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2019 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Sarah M. Romano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2019 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Paul G. Chaney | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2018 | 50,000 | 91,229 (0%) | 0% | 0 | Common Stock | |
| Thomas E. Hancock | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2018 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Praveen Tyle | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2018 | 50,000 | 61,893 (0%) | 0% | 0 | Common Stock | |
| Stephen From | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2018 | 750,000 | 1,159,820 (2%) | 1% | 0 | Common Stock | |
| Michael Manzo | VP of Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2018 | 175,000 | 194,546 (0%) | 0% | 0 | Common Stock | |
| Morton F. Goldberg | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2018 | 50,000 | 59,441 (0%) | 0% | 0 | Common Stock | |
| Bernard Malfroy-Camine | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2018 | 50,000 | 61,525 (0%) | 0% | 0 | Common Stock | |
| Brenda Mann | VP of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2018 | 175,000 | 193,473 (0%) | 0% | 0 | Common Stock | |
| Barbara Wirostko | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2018 | 175,000 | 424,997 (1%) | 0% | 0 | Common Stock | |
| Sarah M. Romano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2018 | 175,000 | 281,863 (0%) | 0% | 0 | Common Stock | |
| Michael Garanzini | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jul 2018 | 25,000 | 196,250 (0%) | 0% | 0 | Common Stock | |
| Barbara Wirostko | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.52 per share. | 07 Jun 2018 | 2,215 | 52,915 (0%) | 0% | 0.5 | 1,152 | Common Stock |
| Barbara Wirostko | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.52 per share. | 07 Jun 2018 | 9,600 | 249,997 (0%) | 0% | 0.5 | 4,992 | Common Stock |
| Barbara Wirostko | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.54 per share. | 07 Jun 2018 | 7,000 | 59,915 (0%) | 0% | 0.5 | 3,780 | Common Stock |
| Stephen From | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 17 Apr 2018 | 125,000 | 409,820 (1%) | 0% | 0 | Common Stock | |
| Stephen From | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 17 Apr 2018 | 125,000 | 125,000 | - | - | Warrants (right to buy) | |
| Sarah M. Romano | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 17 Apr 2018 | 62,500 | 106,863 (0%) | 0% | 0 | Common Stock | |
| Sarah M. Romano | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 17 Apr 2018 | 62,500 | 62,500 | - | - | Warrants (right to buy) | |
| Michael Garanzini | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 17 Apr 2018 | 156,250 | 156,250 | - | - | Warrants (right to buy) | |
| Michael Garanzini | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 17 Apr 2018 | 156,250 | 171,250 (0%) | 0% | 0 | Common Stock | |
| Stephen From | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2018 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Michael Manzo | Vice President of Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2018 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Brenda Mann | VP of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2018 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Barbara Wirostko | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2018 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Sarah M. Romano | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2018 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Stephen From | Director, President and CEO | Other type of transaction at price $ 1.01 per share. | 29 Dec 2017 | 12,355 | 284,820 (1%) | 0% | 1.0 | 12,479 | Common Stock |
| Brenda Mann | VP of Research & Development | Other type of transaction at price $ 1.01 per share. | 29 Dec 2017 | 6,722 | 18,473 (0%) | 0% | 1.0 | 6,789 | Common Stock |
| Barbara Wirostko | Chief Medical Officer | Other type of transaction at price $ 1.01 per share. | 29 Dec 2017 | 12,355 | 240,397 (1%) | 0% | 1.0 | 12,479 | Common Stock |
| Sarah M. Romano | Chief Financial Officer | Other type of transaction at price $ 1.01 per share. | 29 Dec 2017 | 11,863 | 44,363 (0%) | 0% | 1.0 | 11,982 | Common Stock |
| Michael Garanzini | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2017 | 85,000 | 85,000 | - | - | Stock Option (right to buy) | |
| Michael Garanzini | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 1.07 per share. | 17 Nov 2017 | 15,000 | 15,000 (0%) | 0% | 1.1 | 16,050 | Common Stock |
| Barbara Wirostko | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 1.22 per share. | 14 Sep 2017 | 1,200 | 219,042 (1%) | 0% | 1.2 | 1,464 | Common Stock |
| Barbara Wirostko | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 1.20 per share. | 14 Sep 2017 | 9,000 | 228,042 (1%) | 0% | 1.2 | 10,800 | Common Stock |
| Barbara Wirostko | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 1.23 per share. | 14 Sep 2017 | 9,000 | 50,700 (0%) | 0% | 1.2 | 11,070 | Common Stock |
| Sarah M. Romano | Interim CFO | Purchase of securities on an exchange or from another person at price $ 1.00 per share. | 15 Aug 2017 | 10,000 | 32,500 (0%) | 0% | 1 | 10,000 | Common Stock |
| Stephen From | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 1.03 per share. | 10 Aug 2017 | 12,500 | 272,465 (1%) | 0% | 1.0 | 12,875 | Common Stock |
| Paul G. Chaney | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2017 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Thomas E. Hancock | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2017 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Praveen Tyle | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2017 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Stephen From | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2017 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
| Michael Manzo | Vice President of Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2017 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Morton F. Goldberg | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2017 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Thomas Balland | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2017 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Bernard Malfroy-Camine | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2017 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Brenda Mann | VP of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2017 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Barbara Wirostko | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2017 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Sarah M. Romano | Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2017 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Stephen From | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 14 Jun 2017 | 60,000 | 259,965 (1%) | 0% | 0 | Common Stock | |
| Stephen From | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 14 Jun 2017 | 60,000 | 60,000 | - | - | Warrants (right to buy) | |
| Sarah M. Romano | Interim CFO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 14 Jun 2017 | 20,000 | 22,500 (0%) | 0% | 0 | Common Stock | |
| Sarah M. Romano | Interim CFO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 14 Jun 2017 | 20,000 | 20,000 | - | - | Warrants (right to buy) | |
| Paul G. Chaney | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2017 | 17,570 | 0 | - | - | Stock Option (right to buy) | |
| Paul G. Chaney | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.65 per share. | 02 Jun 2017 | 17,570 | 41,229 (0%) | 0% | 0.7 | 11,421 | Common Stock |
| Stephen From | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2017 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Michael Manzo | Vice President of Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2017 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Michael Manzo | Vice President of Engineering | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.65 per share. | 15 May 2017 | 7,285 | 19,546 (0%) | 0% | 0.6 | 4,735 | Common Stock |
| Michael Manzo | Vice President of Engineering | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2017 | 7,285 | 0 | - | - | Stock Option (right to buy) | |
| Barbara Wirostko | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 2.83 per share. | 07 Mar 2017 | 8,700 | 217,842 (2%) | 0% | 2.8 | 24,621 | Common Stock |
| Morton F. Goldberg | None | Sale of securities on an exchange or to another person at price $ 3.00 per share. | 06 Mar 2017 | 8,919 | 9,441 (0%) | 0% | 3 | 26,757 | Common Stock |
| Barbara Wirostko | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 2.60 per share. | 28 Feb 2017 | 41,700 | 41,700 (0%) | 0% | 2.6 | 108,420 | Common Stock |
| Barbara Wirostko | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 2.59 per share. | 28 Feb 2017 | 54,200 | 209,142 (2%) | 0% | 2.6 | 140,378 | Common Stock |
| Morton F. Goldberg | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.70 per share. | 27 Feb 2017 | 1,083 | 18,360 (0%) | 0% | 1.7 | 1,841 | Common Stock |
| Morton F. Goldberg | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2017 | 1,083 | 1,917 | - | - | Stock Option (right to buy) | |
| Stephen From | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2017 | 60,000 | 199,965 (1%) | 0% | 0 | Common Stock | |
| Michael Manzo | Vice President of Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2017 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Brenda Mann | VP of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2017 | 2,500 | 11,751 (0%) | 0% | 0 | Common Stock | |
| Barbara Wirostko | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2017 | 15,000 | 154,942 (1%) | 0% | 0 | Common Stock | |
| Sarah M. Romano | Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2017 | 2,500 | 2,500 (0%) | 0% | 0 | Common Stock | |
| Stephen From | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 15 Sep 2016 | 15,000 | 139,965 | - | - | Common Stock | |
| Ryan R. Brenneman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2016 | 4,568 | 4,568 | - | - | Stock Option (right to buy) | |
| Stephen From | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2016 | 69,152 | 69,152 | - | - | Stock Option (right to buy) | |
| Michael Manzo | Vice President of Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2016 | 15,569 | 15,569 | - | - | Stock Option (right to buy) | |
| Brenda Mann | VP of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2016 | 1,133 | 1,133 | - | - | Stock Option (right to buy) | |
| Barbara Wirostko | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2016 | 4,566 | 4,566 | - | - | Stock Option (right to buy) | |
| Stephen From | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2016 | 52,990 | 124,965 | - | - | Common Stock | |
| Stephen From | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2016 | 52,990 | 0 | - | - | Stock Option (right to buy) | |
| Morton F. Goldberg | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 15 Jun 2016 | 15,000 | 17,277 | - | - | Common Stock | |
| Morton F. Goldberg | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2016 | 3,809 | 0 | - | - | Stock Option (right to buy) | |
| Morton F. Goldberg | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 03 Jun 2016 | 4,650 | 38,566 | - | - | Common Stock | |
| Morton F. Goldberg | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2016 | 14,493 | 0 | - | - | Stock Option (right to buy) | |
| Morton F. Goldberg | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2016 | 5,112 | 0 | - | - | Stock Option (right to buy) | |
| Morton F. Goldberg | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 03 Jun 2016 | 5,543 | 33,023 | - | - | Common Stock | |
| Morton F. Goldberg | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2016 | 5,353 | 0 | - | - | Stock Option (right to buy) | |
| Morton F. Goldberg | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2016 | 2,732 | 0 | - | - | Stock Option (right to buy) | |
| Morton F. Goldberg | None | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 03 Jun 2016 | 746 | 32,277 | - | - | Common Stock | |
| Morton F. Goldberg | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2016 | 2,276 | 0 | - | - | Stock Option (right to buy) | |
| Morton F. Goldberg | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2016 | 33,775 | 43,216 | - | - | Common Stock | |
| Ryan R. Brenneman | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2016 | 41,732 | 41,732 | - | - | Stock Option (right to buy) | |
| Praveen Tyle | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2016 | 7,282 | 7,282 | - | - | Stock Option (right to buy) | |
| Paul G. Chaney | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2016 | 12,647 | 12,647 | - | - | Stock Option (right to buy) | |
| Thomas E. Hancock | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2016 | 2,710 | 2,710 | - | - | Stock Option (right to buy) | |
| Mounia Chaoui | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2016 | 2,416 | 2,416 | - | - | Stock Option (right to buy) | |
| Stephen From | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2016 | 53,531 | 53,531 | - | - | Stock Option (right to buy) | |
| Michael Manzo | Vice President of Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2016 | 12,009 | 12,009 | - | - | Stock Option (right to buy) | |
| Morton F. Goldberg | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2016 | 7,047 | 7,047 | - | - | Stock Option (right to buy) | |
| Thomas Balland | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2016 | 2,416 | 2,416 | - | - | Stock Option (right to buy) | |
| Bernard Malfroy-Camine | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2016 | 4,042 | 4,042 | - | - | Stock Option (right to buy) | |
| Brenda Mann | VP of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2016 | 851 | 851 | - | - | Stock Option (right to buy) | |
| Barbara Wirostko | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2016 | 3,431 | 3,431 | - | - | Stock Option (right to buy) | |
| Brenda Mann | VP of Research & Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2016 | 9,500 | 9,500 | - | - | Stock Option (right to buy) | |
| Brenda Mann | VP of Research & Development | Other type of transaction at price $ 0.00 per share. | 07 Mar 2016 | 9,251 | 9,251 | - | - | Common Stock | |
| Barbara Wirostko | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2016 | 38,286 | 38,286 | - | - | Stock Option (right to buy) | |
| Barbara Wirostko | Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 07 Mar 2016 | 139,942 | 139,942 | - | - | Common Stock | |
| Praveen Tyle | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2016 | 3,000 | 3,000 | - | - | Stock Option (right to buy) | |
| Paul G. Chaney | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2016 | 3,000 | 3,000 | - | - | Stock Option (right to buy) | |
| Thomas E. Hancock | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2016 | 3,000 | 3,000 | - | - | Stock Option (right to buy) | |
| Mounia Chaoui | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2016 | 3,000 | 3,000 | - | - | Stock Option (right to buy) | |
| Stephen From | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2016 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Michael Manzo | Vice President of Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2016 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Morton F. Goldberg | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2016 | 3,000 | 3,000 | - | - | Stock Option (right to buy) | |
| Thomas Balland | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2016 | 3,000 | 3,000 | - | - | Stock Option (right to buy) | |
| Bernard Malfroy-Camine | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2016 | 3,000 | 3,000 | - | - | Stock Option (right to buy) | |
| Praveen Tyle | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2015 | 5,748 | 11,893 | - | - | Common Stock | |
| Praveen Tyle | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2015 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Paul G. Chaney | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2015 | 7,408 | 23,659 | - | - | Common Stock | |
| Paul G. Chaney | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2015 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Thomas E. Hancock | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2015 | 6,519 | 13,487 | - | - | Common Stock | |
| Thomas E. Hancock | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2015 | 2,500 | 2,500 | - | - | Stock Option (right to buy) | |
| Mounia Chaoui | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2015 | 2,500 | 2,500 | - | - | Stock Option (right to buy) | |
| Mounia Chaoui | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2015 | 5,037 | 10,422 | - | - | Common Stock | |
| Stephen From | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2015 | 14,807 | 71,975 | - | - | Common Stock | |
| Stephen From | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2015 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Michael Manzo | Vice President of Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2015 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Michael Manzo | Vice President of Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2015 | 5,926 | 12,261 | - | - | Common Stock | |
| Morton F. Goldberg | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2015 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Morton F. Goldberg | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2015 | 4,563 | 9,441 | - | - | Common Stock | |
| Thomas Balland | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2015 | 5,037 | 10,422 | - | - | Common Stock | |
| Thomas Balland | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2015 | 2,500 | 2,500 | - | - | Stock Option (right to buy) | |
| Bernard Malfroy-Camine | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2015 | 5,570 | 11,525 | - | - | Common Stock | |
| Bernard Malfroy-Camine | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2015 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Praveen Tyle | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2015 | 11,893 | 11,893 | - | - | Common Stock | |
| Paul G. Chaney | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2015 | 15,326 | 23,659 | - | - | Common Stock | |
| Thomas E. Hancock | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2015 | 13,487 | 13,487 | - | - | Common Stock | |
| Mounia Chaoui | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2015 | 10,422 | 10,422 | - | - | Common Stock | |
| Stephen From | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2015 | 30,635 | 71,975 | - | - | Common Stock | |
| Michael Manzo | Vice President of Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2015 | 12,261 | 12,261 | - | - | Common Stock | |
| Morton F. Goldberg | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2015 | 9,441 | 9,441 | - | - | Common Stock | |
| Thomas Balland | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2015 | 10,422 | 10,422 | - | - | Common Stock | |
| Bernard Malfroy-Camine | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2015 | 11,525 | 11,525 | - | - | Common Stock | |
| Praveen Tyle | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2015 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Paul G. Chaney | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2015 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Thomas E. Hancock | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2015 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Mounia Chaoui | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2015 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Stephen From | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2015 | 175,000 | 175,000 | - | - | Stock Option (right to buy) | |
| Michael Manzo | Vice President of Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2015 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Morton F. Goldberg | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2015 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Thomas Balland | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2015 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Bernard Malfroy-Camine | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2015 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Praveen Tyle | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2015 | 2,276 | 36,051 | - | - | Stock Option (right to buy) | |
| Paul G. Chaney | None | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 19 Feb 2015 | 8,333 | 8,333 | - | - | Common Stock | |
| Paul G. Chaney | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2015 | 2,276 | 88,559 | - | - | Stock Option (right to buy) | |
| Thomas E. Hancock | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2015 | 2,276 | 2,276 | - | - | Stock Option (right to buy) | |
| Mounia Chaoui | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2015 | 2,276 | 2,276 | - | - | Stock Option (right to buy) | |
| Stephen From | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2015 | 3,642 | 261,271 | - | - | Stock Option (right to buy) | |
| Michael Manzo | Vice President of Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2015 | 3,187 | 52,973 | - | - | Stock Option (right to buy) | |
| Morton F. Goldberg | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2015 | 2,276 | 36,051 | - | - | Stock Option (right to buy) | |
| Thomas Balland | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2015 | 2,276 | 2,276 | - | - | Stock Option (right to buy) | |
| Bernard Malfroy-Camine | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2015 | 2,276 | 10,631 | - | - | Stock Option (right to buy) |